A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-04

Study Completion Date

2024-05-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity.

Since this is the first study of GEN1053 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN1053 dose to be tested in a larger group of participants and assess preliminary clinical activity of GEN1053.

GEN1053 will be studied in a broad group of cancer patients, having different kinds of solid tumors. All participants will get GEN1053. The study consists of two parts: Part 1 tests increasing doses of GEN1053 ("escalation"), followed by Part 2 which tests the recommended phase 2 dose GEN1053 dose from Part 1 ("expansion").

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

NCT00356460

Carcinoma, Renal Cell Melanoma

COMPLETED PHASE1

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04958434

Locally Advanced or Metastatic Cancers Metastatic Human Papillomavirus-Related Malignant Neoplasm

TERMINATED PHASE1

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

NCT04622774

Advanced Solid Tumor

COMPLETED PHASE1/PHASE2

First Study of the Safety of CNTO 888 in Patients With Solid Tumors

NCT00537368

Cancer

COMPLETED PHASE1

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00816361

Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is a First in Human open-label, multicenter, multinational safety trial in participants with non-central nervous system (non-CNS) metastatic or advanced malignant solid tumors for whom there is no available standard therapy likely to confer clinical benefit, evaluating the safety, tolerability, preliminary antitumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of GEN1053.

The trial will be conducted as follows:

* The Dose Escalation part (Part 1) will explore the safety of escalating doses of GEN1053 as monotherapy (phase 1)
* The Expansion part (Part 2) is planned to provide additional safety and initial antitumor activity information of the Recommended Phase 2 dose (RP2D) for GEN1053 monotherapy in selected tumor indications, as well as more detailed data related to the mode of action (MoA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Sequential assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GEN1053 Monotherapy

Group Type EXPERIMENTAL

GEN1053

Intervention Type BIOLOGICAL

GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GEN1053

GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For both the Dose Escalation and Expansion parts:

* Be ≥18 years of age.
* Have measurable disease according to RECIST 1.1
* Provide all pre-baseline scans since failure of last prior therapy (ie radiographic PD), if available
* Have Eastern Cooperative Oncology Group performance status ≤1.
* Have organ and bone marrow function as follows:

Bone marrow / hematological function:

* Absolute neutrophil count (ANC) ≥1.5×10\^9/L
* Hemoglobin ≥9.0 g/dL
* Platelet count ≥150×10\^9/L

Liver function:

* Total bilirubin ≤ upper limit of normal (ULN)
* Alanine aminotransferase ≤1.5×ULN
* Aspartate aminotransferase ≤1.5×ULN
* Albumin ≥30 g/L

Coagulation status:

* Prothrombin time (PT)/International normalized ratio ≤1.5
* Activated partial thromboplastin time (aPTT) ≤1.5×ULN
* Renal function: Glomerular filtration rate ≥45 mL/min/1.73 m², according to the abbreviated Modification of Diet in Renal Disease equation

For Monotherapy Dose Escalation (phase 1) only:

* Subjects with histologically or cytologically confirmed non-CNS solid tumors that are metastatic or advanced.
* Subjects who have progressed on standard of care therapy or for whom there is no available standard therapy likely to provide clinical benefit, or who are not candidates for or refuse such available therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN1053 may be beneficial.
* Fresh biopsies mandatory for all patients in Monotherapy Dose Escalation

For the Expansion part Only:

•Subjects with histologically or cytologically confirmed diagnosis of recurrent, unresectable or metastatic HNSCC, who have progressed on standard of care therapy or do not have any further available standard therapy or are not candidates for or refuse standard therapy (if subjects had access), and for whom experimental therapy with GEN1053 may be beneficial in the opinion of the investigator.

Exclusion Criteria

* Has uncontrolled intercurrent illness, including but not limited to:

* Ongoing or active infection requiring IV treatment with anti-infective therapy administered less than 2 weeks prior to first dose.
* Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris or cardiac arrhythmia.
* Uncontrolled hypertension defined as systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, despite optimal medical management.
* Prolonged QTc interval at baseline of ≥470 milliseconds using Fridericia's QT correction formula.
* Ongoing or recent (within 1 year) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs.
* History of grade 3 or higher irAEs that led to treatment discontinuation of a CPI.
* History of chronic liver disease or evidence of hepatic cirrhosis.
* Evidence of interstitial lung disease.
* Ongoing pneumonitis or history of non-infectious pneumonitis that has required steroids.
* Known platelet function defects
* Prior therapy:

* Radiotherapy within 14 days prior to first GEN1053 administration. Palliative radiotherapy will be allowed.
* Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1053 administration.
* Subject with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment. Inhaled or topical steroids, and adrenal or pituitary replacement steroid \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No